Add BrightSurf on Google Email

Characterizing antibodies targeting antisense oligonucleotide modifications

Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 31, 2025

Research opens up new avenue for Tuberculosis drug discovery

Scientists from the University of Bath have identified two new families of chemical compounds that inhibit alpha-methylacyl-CoA racemase (MCR) in Mycobacterium tuberculosis, a key enzyme for TB survival. This breakthrough could lead to new treatments for TB and potentially other diseases like prostate cancer.

SourceUniversity of Bath·JournalJournal of Biological Chemistry·TypeExperimental study·DateJul 2, 2025

Chinese Medical Journal article reviews classification, synthesis, and applications of ‘herbzymes’

Researchers review nanozymes derived from Chinese herbs, including their catalytic properties, biomedical applications, and potential challenges in developing herbzymes for practical use. The review highlights three main types of herbzymes: herb carbon dot enzymes, polyphenol-metal nanozymes, and herb extract nanozymes.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateJun 6, 2025

Experimental Drug Development Centre granted US FDA fast track designation for antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma

The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.

New study advances cancer precision therapies by identifying patients who benefit from Bexmarilimab treatment

A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.

SourceUniversity of Turku·JournalJournal for ImmunoTherapy of Cancer·DateMay 20, 2025

Rediscovering denosumab: From osteoporosis treatment towards a possible role against breast cancer

Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBreast Cancer Research·TypeRandomized controlled/clinical trial·DateMay 16, 2025

AACR 2025: Colon cancer risk reduction, predicting melanoma spread and new drug therapies among Ohio State findings

Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.

Study finds protein partnership protects chromosomes

A new study from Weill Cornell Medicine reveals a critical protein partnership that protects chromosome ends, regulating telomerase activity and preventing cell death. The researchers discovered that the CST complex and DNA polymerase α/primase interact to maintain telomere stability, with disruption leading to telomere abnormalities.

SourceWeill Cornell Medicine·JournalNucleic Acids Research·DateApr 17, 2025

Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment

Researchers developed a bispecific killer engager that selectively depletes PD-1 positive lymphocytes, a promising avenue for treating autoimmune diseases. The bike technology enhances NK cell-mediated apoptosis and depletion of activated immune cells, supporting its potential as a safe and potent tool.

SourceCompuscript Ltd·JournalActa Pharmaceutica Sinica B·DateApr 13, 2025

Osteoarthritis: largest genome-wide association study uncovers drug targets and therapy opportunities

The largest genome-wide association study on osteoarthritis identifies over 900 genetic associations, including 700 genes involved in the disease. These findings offer new insights into the genetic landscape of osteoarthritis and potential drug repurposing opportunities.

Researchers identify safer pathway for pain relief

A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...

SourceUniversity of Florida·JournalNature Communications·TypeExperimental study·DateApr 8, 2025

Some gut bacteria could make certain drugs less effective

A new study reveals that specific gut bacteria can break down certain drugs, altering their efficacy. The research found that 30 out of 127 tested drugs were heavily metabolized by human gut microbiota, potentially reducing their effectiveness. The study's findings could have significant implications for personalized medicine and drug ...

SourceUniversity of Pittsburgh·JournalNature Chemistry·DateApr 3, 2025

COVID-19 boosters help avoid breakthrough infections in immunocompromised people, McGill-led study finds

A new study by researchers at McGill University found that annual COVID-19 vaccine booster doses help avoid breakthrough infections in people with immune-mediated inflammatory diseases. The study tracked 366 patients across Canada and used saliva PCR tests and antibody measurements, offering a more precise picture of infection risks.

SourceMcGill University·JournalVaccine·TypeObservational study·DateMar 31, 2025